Healthy volunteers help test new drug NAV-240 for first time in humans
NCT ID NCT06933043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a new drug, NAV-240, in 24 healthy adults. Participants received either the drug or a placebo to see what side effects might occur. The goal was to gather initial safety information, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Brisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 10-second sprint may reveal who gains the most muscle from weight training
- Can a needle and a zap boost athletic performance? a trial puts five nerve-stimulation patterns to the test.
- Can an inhaled powder stop lung scarring? a safety trial begins
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Could a gentle buzz behind the ears tune your heart's rhythm?
- Training Non-Radiology staff to take X-Rays: a feasibility test